KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease-Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis-Stimulating Agent Dose.

Alan Jardine, Steven K Burke, Wenli Luo, Todd Minga, Mark J Sarnak, Wolfgang C Winkelmayer, Rajiv Agarwal, Glenn M Chertow, Kai-Uwe Eckardt, Mark J Koury

Hemodial Int 30(1) 80-100

PMID41376433
PMCIDPMC12817161
DOI10.1111/hdi.70034
发表日期2025-12-11
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 forest plot;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。
摘要

摘要

INTRODUCTION: Erythropoiesis-stimulating agents (ESAs) and iron supplementation are standard treatments for chronic kidney disease (CKD)-related anemia. Targeting higher hemoglobin values in CKD increases cardiovascular risk. Whether the increased risk is from higher ESA doses or higher hemoglobin levels is uncertain, but alternative therapies are sought for patients requiring high ESA doses. Phase 3 INNO2VATE trials in patients with dialysis-dependent CKD (DD-CKD) demonstrated vadadustat's noninferiority compared with darbepoetin alfa. To determine vadadustat's potential to treat anemia, including in patients requiring high ESA doses, its safety and efficacy were compared with those of darbepoetin alfa across prespecified baseline ESA dose subgroups in the prevalent DD-CKD INNO2VATE trial. METHODS: We compared the safety and efficacy of vadadustat versus darbepoetin alfa across prespecified baseline ESA dose subgroups (low [≤ 90 U/kg/week], intermediate [> 90 and < 300 U/kg/week], or high [≥ 300 U/kg/week]) in the INNO2VATE prevalent trial. The primary safety endpoint was time to first adjudicated major adverse cardiovascular event (MACE). Primary and secondary efficacy endpoints were mean hemoglobin level change from baseline at weeks 24-36 and weeks 40-52, respectively. FINDINGS: Compared with darbepoetin alfa, first MACE hazard ratios for vadadustat were 0.99 (95% CI, 0.81-1.23), 0.93 (95% CI, 0.74-1.18), and 0.62 (95% CI, 0.34-1.14) for low, intermediate, and high baseline ESA dose subgroups, respectively (interaction p = 0.92). Vadadustat was noninferior to darbepoetin alfa in hemoglobin change from baseline to primary evaluation period, with mean differences (vadadustat-darbepoetin alfa) of -0.10 g/dL (95% CI, -0.19 to -0.02), -0.20 g/dL (95% CI, -0.30 to -0.09), and -0.39 g/dL (95% CI, -0.67 to -0.11) for low, intermediate, and high ESA dose subgroups, respectively. DISCUSSION: Comparing safety and efficacy by baseline ESA dose among patients with CKD on maintenance dialysis, vadadustat was noninferior to darbepoetin alfa for all ESA dose subgroups, including patients with high baseline ESA requirements.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Prespecified MACE analysis by baseline ESA dose in patients with prevalent DD‐CKD (safety population). Any MACE plus hospitalizations for heart failure or thromboembolic events excluding vascular access thrombosis. DD‐CKD, dialysis‐dependent chronic kidney disease; ESA, erythropoiesis‐stimulating agent; MACE, major adverse cardiovascular events.
非 KM Figure
FIGURE 2FIGURE 2 Mean hemoglobin over time by baseline ESA dose in patients with prevalent DD‐CKD. Geography‐specific target range for hemoglobin: 10–11 g/dL in the USA and 10–12 g/dL in other countries. DD‐CKD, dialysis‐dependent chronic kidney disease; ESA, erythropoiesis‐stimulating agent; PEP, primary evaluation period; SEP, secondary evaluation period.
非 KM Figure
FIGURE 3FIGURE 3 Daily vadadustat dose over the primary and secondary evaluation periods by baseline ESA dose (safety population). This analysis includes only those patients who were receiving vadadustat and not those whose doses were interrupted due to elevated hemoglobin levels, ESA rescue, or adverse events. ESA, erythropoiesis‐stimulating agent; PEP, primary evaluation period; SEP, secondary evaluation period.
非 KM Figure